Uracil/tegafur plus oral calcium folinate in advanced breast cancer

被引：0

作者：

Richardet, E ^{[1
]}

Pedraza, C ^{[1
]}

Mickiewicz, E ^{[1
]}

Lerzo, G ^{[1
]}

Bonamasa, M ^{[1
]}

Coppola, F ^{[1
]}

Elli, A ^{[1
]}

Uranga, G ^{[1
]}

Jovtis, S ^{[1
]}

Bruno, M ^{[1
]}

Ventriglia, M ^{[1
]}

Cuevas, MA ^{[1
]}

Alvarez, AM ^{[1
]}

Suarez, LA ^{[1
]}

Fein, L ^{[1
]}

机构：

[1] Univ Catolica Cordoba, Carrera Postgrad Oncol, RA-5000 Cordoba, Argentina

来源：

ONCOLOGY-NEW YORK | 1999年 / 13卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is deliver-ed in an easy-to-administer oral formulation Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide evert greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase II trial investigating the feasibility of 250 mg/m(2)/day of UFT phs 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and art overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation.

引用

页码：96 / 97

页数：2

共 50 条

[21] Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC)
Goker, E
Aykan, NF
Serdengecti, S
Gunel, N
Alakavuklar, M
Icli, F
Yucel, I
Uskent, N
Arpaci, F
Firat, D
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
[22] Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma
Hoff, PM
Pazdur, R
ONCOLOGY-NEW YORK, 1999, 13 (07): : 48 - 50
[23] UFT plus calcium folinate/irinotecan in colorectal cancer
Twelves, C
ONCOLOGY-NEW YORK, 1999, 13 (07): : 51 - 54
[24] Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer
Hoff, PM
Janjan, N
Saad, ED
Skibber, J
Crane, C
Lassere, Y
Cleary, KR
Benner, S
Randolph, J
Abbruzzese, JL
Pazdur, R
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) : 3529 - 3534
[25] Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
Alliot, C
BRITISH JOURNAL OF CANCER, 2004, 91 (06) : 1220 - 1221
[26] Phase II Study of Tegafur/Uracil and Leucovorin plus Bevacizumab for Elderly Patients with Advanced Colorectal Cancer
Murata, Kohei
Mizushima, Tsunekazu
Tamagawa, Koji
Matsuda, Chu
Fukunaga, Mutsumi
Hata, Taishi
Nezu, Riichiro
Yamamoto, Hirofumi
Doki, Yuichiro
Mori, Masaki
ANNALS OF ONCOLOGY, 2016, 27
[27] A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada
Maroun, JA
Asche, C
Romeyer, F
Mukherjee, J
Cripps, C
Oza, A
Skillings, JR
Letarte, J
PHARMACOECONOMICS, 2003, 21 (14) : 1039 - 1051
[28] A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada
Jean A. Maroun
Carl Asche
Françoise Romeyer
Jayanti Mukherjee
Christine Cripps
Amit Oza
Jamie R. Skillings
Jacques Letarte
PharmacoEconomics, 2003, 21 : 1039 - 1051
[29] An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report
Masatsugu Hiraki
Toshiya Tanaka
Futa Koga
Akimasa Saito
Noriko Oza
Osamu Ikeda
Tatsuya Manabe
Atsushi Miyoshi
Kenji Kitahara
Seiji Sato
Hirokazu Noshiro
Journal of Gastrointestinal Cancer, 2020, 51 : 296 - 299
[30] Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
C Alliot
British Journal of Cancer, 2004, 91 : 1220 - 1221

← 1 2 3 4 5 →